The Architectural Turn in Depression Why Network Topology Will Redefine CNS Strategy

 


By Denis Katz, MD, MHA
Founder, Salience Clinical

For decades, psychiatry has framed major depressive disorder (MDD) as a disorder of neurochemistry—an imbalance of serotonin, norepinephrine, or dopamine. This paradigm has delivered meaningful therapeutic advances. Yet it has not consistently achieved durable remission for a substantial proportion of patients. Approximately one-third remain treatment-resistant, and relapse among responders is common. Incremental modulation of synaptic signaling appears to be approaching a ceiling in its capacity to transform long-term outcomes at scale.

The next shift in neuropsychiatry will not be chemical.
It will be architectural.

By “architectural,” we refer to the topology, coupling, and dynamic switching behavior of large-scale brain networks that govern how information is processed and regulated.

From Neurotransmitters to Networks

Advances in high-resolution functional MRI, multimodal imaging, and computational modeling have fundamentally reshaped our understanding of depression. MDD is now consistently associated with dysregulation across three large-scale systems—often termed the triple network:

  • Salience Network (SN): Detects and prioritizes internal and external stimuli while coordinating switching between networks.

  • Central Executive / Frontoparietal Network (CEN/FPN): Governs cognitive control, working memory, and goal-directed behavior.

  • Default Mode Network (DMN): Supports self-referential processing and autobiographical memory, but when dysregulated, contributes to maladaptive rumination.

In this framework, what matters is not simply neuronal activity, but how these networks interact—and which dominates at a given moment.

In MDD, research consistently shows:

  • Reduced anticorrelation between DMN and executive networks

  • Abnormal coupling between salience and DMN/CEN systems

  • Impaired salience-driven switching between networks

In treatment-resistant subtypes, these disruptions are often more pronounced, reflecting deeper architectural instability across salience, executive, and default mode circuits.

Collectively, these findings point to a systems-level imbalance—an architectural dysfunction in network coordination—rather than a purely localized neurotransmitter deficit.

The Strategic Implication: Signal Modulation Is Not Enough

Traditional pharmacotherapies primarily modulate synaptic transmission. Neuromodulation approaches—such as rTMS, ECT, and invasive stimulation—alter excitability within specific brain regions.

However, most existing interventions were not designed to explicitly recalibrate the interaction and proportional balance of large-scale networks.

We have been adjusting signal intensity.
We have not been engineering network behavior.

If executive systems remain under-recruited while default or salience systems remain overactive or poorly regulated, symptom improvement may occur without durable architectural correction—potentially explaining relapse vulnerability in many patients.

This reframes the central question for CNS innovation:

Can we design interventions that restore network reciprocity, flexibility, and switching—not just neurotransmission?

Toward Network-Level Rebalancing

The future of precision psychiatry will likely be defined by:

  • Imaging-informed stratification: Using connectivity patterns to identify biologically grounded patient subtypes and predict response

  • Network-based endpoints: Incorporating measures of connectivity, flexibility, and switching alongside clinical outcomes

  • Closed-loop neuromodulation: Leveraging biomarkers to guide real-time, individualized stimulation strategies

  • Plasticity-oriented biologics: Developing agents that reshape network connectivity in addition to synaptic signaling

  • Targeted behavioral and digital interventions: Designed to strengthen executive control while reducing maladaptive DMN dominance and aberrant salience attribution

This is not a rejection of neurochemistry—it is its integration into a systems-level framework. Synapses operate within circuits. Circuits operate within networks. Networks define cognitive architecture.

Strategic Implications for Pharma and MedTech

1. Drug Development

Compounds should be evaluated not only by symptom reduction, but by their impact on network connectivity and dynamics. Early integration of network-level biomarkers can:

  • Differentiate mechanisms of action

  • Inform dose optimization

  • Identify responder populations

2. Clinical Trial Design

Connectivity-based biomarkers can:

  • Enable biologically informed stratification

  • Reduce heterogeneity-driven signal dilution

  • Provide early indicators of treatment trajectory

Programs that embed these metrics into trial design will be better positioned for regulatory, payer, and partnership discussions.

3. Medical Affairs Narrative

The “chemical imbalance” model is increasingly outdated. A network-based narrative:

  • Aligns with contemporary neuroscience

  • Strengthens scientific credibility

  • Supports integrated pharmacologic and device strategies

4. Durable Remission Strategy

Long-term outcomes may depend on restoring:

  • Efficient network switching

  • Appropriate salience gating

  • Robust executive engagement

Architectural normalization—not just symptom suppression—may be the key to sustained remission.

A Practical Illustration

Consider a future treatment-resistant depression program that combines:

  • A rapid-acting neuroplasticity-enhancing agent

  • Connectivity-guided rTMS targeting

Success would be defined not only by symptom improvement, but by restoration of balance across DMN, CEN, and SN networks.

This is the operationalization of architecture—moving beyond chemistry in isolation.

The Competitive Inflection Point

We are entering a phase where:

  • Network neuroscience can directly inform development strategy

  • Computational and graph-based models can predict treatment response

  • Neuromodulation platforms are increasingly programmable and biomarker-driven

  • Multimodal datasets enable biologically grounded stratification

Organizations that integrate network architecture into R&D, trial design, and lifecycle strategy will define the next decade of CNS therapeutics.

Those that remain chemistry-centric will face diminishing marginal returns.

The Salience Clinical Perspective

At Salience Clinical, we focus on translating systems neuroscience into actionable strategy—across clinical development, biomarker integration, and translational positioning.

Our work is not theoretical. It is applied architecture.

We help teams move from insight to execution—embedding network science into pipelines, endpoints, and evidence strategies.

The next transformation in psychiatry will not come from louder drugs.

It will come from smarter maps.

Comments

Post a Comment

Popular posts from this blog

Post-Market Surveillance Best Practices for Advanced Wound Care Devices: Expert Insights

Image
Post-Market Surveillance Best Practices for Advanced Wound Care Devices: Expert Insights By Denis Katz, MD — Founder & Principal, Katz Medical Affairs Consulting | Specialist in Medical Device Compliance & Post-Market Surveillance In today’s MedTech landscape, post-market surveillance (PMS) has evolved from a regulatory checkbox to a strategic driver of patient safety, clinical evidence, and market success. Advanced wound care devices, given their complex patient populations and diverse surgical applications , demand tailored  PMS approaches  that address unique clinical and regulatory challenges. Drawing on extensive experience in medical affairs and compliance, this analysis outlines practical strategies for effective PMS implementation, illustrated through the case study of Solventum’s Prevena Restor Incision Management System the first negative pressure wound therapy device to receive FDA clearance to aid in reducing superficial surgical site infections in certain ...
Read more

The Architectural Turn in Depression Why Network Topology Will Redefine CNS Strategy

Image
The Architectural Turn in Depression Why Network Topology Will Redefine CNS Strategy By Denis Katz, MD, MHA Founder, Salience Clinical, LLC For decades, psychiatry has framed major depressive disorder (MDD) as a  disorder of chemistry , an imbalance of serotonin, norepinephrine, or dopamine. That model produced meaningful therapeutic advances, yet it has not consistently delivered durable remission for a substantial proportion of patients. Roughly one-third remain treatment resistant, and among responders, relapse is common. Incremental modulation of synaptic signaling alone appears to have reached a ceiling in its ability to transform long-term outcomes at scale. The next shift in neuropsychiatry will not be chemical. It will be architectural. By “architectural,” we mean the topology, coupling, and switching behavior of large-scale brain networks that shape how information is processed. From neurotransmitters to networks Advances in high-resolution functional MRI, multimodal imagi...
Read more

Navigating Regulatory Hurdles in Alzheimer’s Drug Development

Image
  Protecting Sponsor Capital, Managing Risk, and Maximizing Probability of Success Denis Katz, MD, MHA Clinical Scientist & Development Strategist Founder, Salience Clinical, LLC Executive Summary Alzheimer’s disease (AD) drug development remains the highest-stakes arena in biopharma. While the "Alzheimer’s Graveyard" is littered with multi-billion dollar failures, a new era of amyloid and tau-targeting therapies has proven that the regulatory path is navigable—but only for those with a disciplined risk architecture. Success in 2026 is driven by Translational Clarity : the ability to prove that biological changes translate into human functional benefit. The Success Gap ●        99.6%: Historical failure rate (2002–2012). ●        18 Years: The approval drought between novel disease-modifying therapies (2003–2021). ●        $300M+: The average sunk R&D cost of...
Read more